FDA Approves First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes

Last Updated: Aug 28, 2024

The U.S. Food and Drug Administration expanded the indications of the Insulet SmartAdjust technology, an interoperable automated glycemic controller previously indicated for the management of type 1 diabetes in individuals two years and older, to also include management of type 2 diabetes in individuals 18 years and older. Read more.